Neoprobe to Present at Wall Street Analyst Forum; CFO To Provide Business Update.DUBLIN, Ohio -- Please replace the release dated September 21, 2006 with the following corrected version due to multiple revisions to the headline and text.
The corrected release reads:
NEOPROBE TO PRESENT AT WALL STREET ANALYST FORUM; CFO See Chief Financial Officer. TO PROVIDE BUSINESS UPDATE
Neoprobe Corporation (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :NEOP NEOP Neoprobe Corporation (stock symbol)
NEOP Near Earth Object Program
NEOP New England Order of Protection
NEOP Nuclear Explosive Operating Procedure ), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that its Vice President, Finance and Chief Financial Officer, Brent Larson, will present tomorrow, September 28, 2006 at 11:10 a.m. EDT EDT
Eastern Daylight Time
EDT Eastern Daylight Time
EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York
EDT , during the 17th Annual Wall Street Analyst Forum to be held at the Princeton Club in New York, NY.
Interested parties can access a live, or archived, internet broadcast of the presentation at:
The presentation will be archived for 30 days.
Neoprobe is a biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.
2. Of, relating to, or involving biological, medical, and physical sciences. company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000[R] line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix([R]) line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes. agents including Lymphoseek[R] and RIGScan([R]) CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com